US Edition
Published • loading... • Updated
Mergers and Acquisitions (M&A): Gilead Sciences to Acquire Arcellx (NASDAQ: ACLX) for $7.8 Billion
Summary by Intelligence360 News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Mergers and Acquisitions (M&A): Gilead Sciences to Acquire Arcellx (NASDAQ: ACLX) for $7.8 Billion
Foster City, CA – Gilead Sciences has announced the acquisition of Arcellx (https://www.arcell/). According to the company announcement, Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, includi…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
